SCHEMBL4977359

SCHEMBL4977359

CS(=O)(=O)c1nccc(-c2[nH]c(-c3ccccc3)nc2-c2ccc(F)cc2)n1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.56
MAPK11 Q15759 6/20 0.55
MAPK13 O15264 5/20 0.55
MAPK12 P53778 5/20 0.55
ALOX5 P09917 4/20 0.55
RAF1 P04049 3/20 0.55
MAPK9 P45984 3/20 0.55
GCGR P47871 2/20 0.55
CSNK1D P48730 3/20 0.55
ALDH1A1 P00352 1/20 0.55
CSNK1A1 P48729 1/20 0.55
CSNK1E P49674 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CSNK1A1L Q8N752 1/20 0.55
TGFBR1 P36897 1/20 0.54
EGFR P00533 2/20 0.53
JAK3 P52333 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4974887 0.80 MAPK14 (0.81) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL4975933 0.76 MAPK14 (0.85) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL2410945 0.76 RAB9A (0.56) ALDH1A1SMN1; SMN2TGFBR1
SCHEMBL4552049 0.76 ALOX5 (0.73) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL5771534 0.75 MAPK13 (0.46) MAPK14MAPK11MAPK13MAPK12
SCHEMBL7485716 0.75 MAPK14 (0.63) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL1629037 0.75 MAPK13 (0.85) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL16292225 0.75 MAPK13 (0.85) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL5770353 0.74 MAPK13 (0.45) MAPK14MAPK11MAPK13MAPK12
SCHEMBL5770929 0.74 MAPK13 (0.53) MAPK14MAPK11MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101426503-A Compositions and methods of treatment for inhibiting kinase and/or HMG-COA reductase PHARMIX CORP (US) 2009-05-06 CN disclosed
US-20080021054-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2008-01-24 US disclosed
US-20080021054-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2008-01-24 US disclosed
US-20080021054-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2008-01-24 US disclosed
US-7199126-B2 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase PHARMIX CORPORATION (US) 2007-04-03 US disclosed
US-7199126-B2 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase PHARMIX CORPORATION (US) 2007-04-03 US disclosed
US-7199126-B2 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase PHARMIX CORPORATION (US) 2007-04-03 US disclosed
EP-1755607-A2 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE Pharmix Corporation (US) 2007-02-28 EP disclosed
US-7183285-B2 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase PHARMIX CORP. (US) 2007-02-27 US disclosed
US-7183285-B2 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase PHARMIX CORP. (US) 2007-02-27 US disclosed
US-20070004758-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2007-01-04 US disclosed
US-20070004758-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2007-01-04 US disclosed
US-20070004758-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2007-01-04 US disclosed
US-20060084695-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2006-04-20 US disclosed
WO-2006028524-A2 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE PHARMIX CORPORATION (US) 2006-03-16 WO disclosed
US-20050288306-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-12-29 US disclosed
US-20050282883-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-12-22 US disclosed
US-20050277653-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-12-15 US disclosed
US-20050272770-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-12-08 US disclosed
US-20050261354-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288306-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase HMGCR, HMGB3, HMGB2 MAPK14 198/4885MAPK11 213/4885MAPK13 189/4885
US-20050282883-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase HMGCR, HMGB3, HMGB2 MAPK14 224/4885MAPK11 235/4885MAPK13 201/4885
US-20060084695-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase HMGCR, HMGB3, HMGB2 MAPK14 198/4885MAPK11 213/4885MAPK13 189/4885
US-20050277653-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase HMGCR, HMGB3, HMGB2 MAPK14 198/4885MAPK11 213/4885MAPK13 189/4885
US-20070004758-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE HMGCR, HMGB3, HMGB2 MAPK14 198/4885MAPK11 213/4885MAPK13 189/4885
US-20050261354-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase HMGCR, HMGB3, HMGB2 MAPK14 198/4885MAPK11 213/4885MAPK13 189/4885
US-20080021054-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE HMGCR, HMGB3, HMGB2 MAPK14 198/4885MAPK11 213/4885MAPK13 189/4885
US-20050272770-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase HMGCR, HMGB3, HMGB2 MAPK14 198/4885MAPK11 213/4885MAPK13 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.